Diametric Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Diametric Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,077	Closed	-$211K	–	515
2024 Q2	$211K	Buy	+3,077	New	+$213K	0.11%	269

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diametric Capital's ITCI Position: Q3 2024 in Review

Diametric Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 3,077 shares — an estimated $211K sold.

Diametric Capital first reported a position in ITCI in Q2 2024 and held it in 1 quarter. The position peaked at $211K in Q2 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Diametric Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Diametric Capital sold 3,077 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $211K.
Diametric Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 1 quarter.
Diametric Capital's Intra-Cellular Therapies Inc. position peaked at $211K in Q2 2024.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Diametric Capital's 13F filing for Q3 2024, filed 13 Nov 2024.